Many more examples of early PDUFA dates 2019- see comments re three months early- single arm trials- astoundingly high launch prices
https://www.raps.org/News-and-Articles/News-Articles/2019/11/FDA-Approves-5-New-Costly-Drugs-Well-Ahead-of-Acti
Since 21 October, the US Food and Drug Administration (FDA) has been on a tear in approving five new drugs (all with list prices of more than $100,000 per year) months ahead of when they were expected to be approved.
For instance, FDA signed off on Vertex Pharmaceuticals’ Trikafta (elexacaftor/ivacaftor/tezacaftor), a new treatment for those with the most common cystic fibrosis mutation, after only three months of review and well ahead of its 19 March 2020 user fee action date.
She also explained how the high number of approvals in recent years for rare diseases may be influencing this perception of a lower bar, especially as more treatments are approved on the basis of a single-arm study or with an external control group. In addition, she pointed to the “astoundingly” high launch prices for some of these rare disease treatments that may also be part of the reason for the pushback.
No reason Ryoncil not approved by Si's bedside chat end of August- so I've just reloaded- missed the 90's- lets goooooooooooooooo
The FDA changed it's mind " After additional consideration" - I'm not going to sit on the sidelines- All in
Reg
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-202
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 274918 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 974 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 103162 | 0.970 |
5 | 34741 | 0.965 |
11 | 125566 | 0.960 |
1 | 500 | 0.955 |
22 | 165429 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 974 | 1 |
0.990 | 10204 | 1 |
1.000 | 14000 | 1 |
1.010 | 2877 | 1 |
1.015 | 60000 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
MSB (ASX) Chart |